Your shopping cart is currently empty

CK-571 is a potent and selective inhibitor of smooth muscle myosin-2 (SMM) with an IC50 of 86 nM. The compound exhibits IC50 values of 2.3, 42, and 0.58 μM for cardiac myosin (CMM), skeletal muscle myosin (SKM), and non-muscle myosin-2A (NMM-2A), respectively. CK-571 is utilized in research on asthma, chronic obstructive pulmonary disease, and other smooth muscle-related disorders.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | CK-571 is a potent and selective inhibitor of smooth muscle myosin-2 (SMM) with an IC50 of 86 nM. The compound exhibits IC50 values of 2.3, 42, and 0.58 μM for cardiac myosin (CMM), skeletal muscle myosin (SKM), and non-muscle myosin-2A (NMM-2A), respectively. CK-571 is utilized in research on asthma, chronic obstructive pulmonary disease, and other smooth muscle-related disorders. |
| Molecular Weight | 504.94 |
| Formula | C24H26ClFN4O5 |
| Cas No. | 1119536-89-8 |
| Smiles | N(C(OC[C@@H](N(C(NCC1=C(Cl)C(F)=CC=C1)=O)C)C[C@H](CO)O)=O)C2=CC3=C(C=N2)C=CC=C3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.